Check Claims Before You Publish

 Quick Explanation Copied

 Long Explanation

Citation Profile and Trajectory

Charles Dearman's bibliometric footprint is small but real and rising. OpenAlex reports 17 works, 248 cumulative citations, and an h-index of 6, whereas Semantic Scholar records a narrower 12 papers, 191 citations, and h-index 4 — a discrepancy typical of incomplete indexing rather than inflated metrics. Publication years cluster in 2015 (5 works, 68 citations) and 2019–2020 (4 works, 150 citations), with a gap in 2021–2022 followed by renewed output in 2023–2025, much of it open access OpenAlex author record.

What the Work Itself Shows

Two substantive review articles anchor his citation record. The gastrointestinal immunotherapy review, with senior UCL authors, has drawn 77 citations and sits in a high-impact journal GI immunotherapy review, 77 citations, and the EGFR heterogeneity review with Royal Marsden leadership (Cunningham, Chau, Starling) has 68 citations EGFR resistance review, 68 citations. Both are middle-author contributions to senior-led teams, so citation counts reflect team and venue prestige as much as individual scientific leadership. His only clear first-author high-venue paper is a brief Lancet Oncology correspondence on surgery versus SABR (13 citations, 3 references) Lancet Oncology SABR commentary, plus a structured best-evidence topic on tranexamic dosing in cardiac surgery Tranexamic acid best-evidence topic.

Notably, since ~2023 he has shifted to environmental/public-health research from UKHSA and LSHTM: an SUV emissions public health model SUV emissions health model, a systematic review of cooling centres Cooling centres systematic review, and the PAICE health-equity/climate policy programme PAICE climate-health project. This pivot demonstrates methodological range (modelling, systematic review, policy science) but raises the classic blindspot of a diffuse portfolio: no single deep expertise has yet consolidated.

Critical Assessment and Confidence

Known: a competent, well-networked clinician-researcher whose most-cited work is collaborative reviews. Inferred: positions on papers and venue prestige, rather than first-author data-driven studies, drive the citation metrics — a common early-career pattern that inflates apparent impact. Uncertain: missing affiliation metadata on OpenAlex, a 2021–2022 publication gap, and absence of clinical-trial leadership or primary first-author data papers prevent assessment of independent scientific leadership. What would change this verdict: first-author prospective studies or trial leadership in either oncology or environmental health with independent replication and sustained citation growth.

 BGPT Author Review

Scientific Quality

Small record: h-index 6 (OpenAlex)/4 (Semantic Scholar), 248 citations over 17 works, mostly reviews and correspondence, with two heavily cited middle-author reviews in senior-led teams. No first-author original research with major impact yet. Recent pivot to environmental health shows methodological breadth but no consolidated independent programme. Affiliations missing from OpenAlex limit verification.

Communication Quality

Publications appear in clear, well-structured venues including structured best-evidence topics and open-access policy-adjacent work, suggesting competent, accessible scientific writing. However, most high-cited work is middle-authored, so individual communication skill cannot be isolated.

Author Novelty

The two citation anchors are reviews of established fields (GI immunotherapy, EGFR resistance), not conceptual breakthroughs. The SUV public-health model and cooling-centre review touch a less-crowded niche, offering moderate novelty, but no paradigm-shifting contribution is evident.

Scientific Rigor

The tranexamic best-evidence topic and cooling-centre systematic review follow transparent, structured methods, and the SUV study is an explicit modelling exercise with open access. Counterweights: reviews synthesize others' data, the Lancet Oncology piece is a 3-reference commentary, and no primary trial-level first-author evidence exists to judge rigor at full strength.